REDWOOD CITY, CA, Kriya Therapeutics, a fully integrated gene therapy company pioneering novel technologies and therapeutics, announced a $270 Million Series C financing.

The financing was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors.